Differential selection of acridine resistance mutations in human DNA topoisomerase IIβ is dependent on the acridine structure

Molecular Pharmacology

Volumn 71, Issue 4, 2007, Pages 1006-1014

  Leontiou, Chrysoula ^a,b   Watters, Gary P ^a   Gilroy, Kathryn L ^a   Heslop, Pauline ^a   Cowell, Ian G ^a   Craig, Kate ^a   Lightowlers, Robert N ^a   Lakey, Jeremy H ^a   Austin, Caroline A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II BETA; METHYL N (4' (9 ACRIDINYLAMINO) 2 METHOXY PHENYL) CARBAMATE HYDROCHLORIDE; METHYL N (4' (9 ACRIDINYLAMINO) 3 METHOXY PHENYL) METHANE SULFONAMIDE; METHYL N (4' (9 ACRIDINYLAMINO) PHENYL) CARBAMATE HYDROCHLORIDE; N [2 (DIMETHYLAMINO) ETHYL] ACRIDINES 4 CARBOXAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; CROSS RESISTANCE; DNA BINDING; DRUG RESISTANCE; HETERODUPLEX ANALYSIS; IN VITRO STUDY; MOLECULAR EVOLUTION; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ACRIDINES; DIRECTED MOLECULAR EVOLUTION; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE; HUMANS; MOLECULAR STRUCTURE; MUTATION, MISSENSE; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33947368522     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.032953     Document Type: Article

References (33)

1. Austin CA and Marsh KL (1998) Eukaryotic DNA topoisomerase IIβ. Bioessays 20:215-226.
2. Austin CA, Marsh KL, Wasserman RA, Willmore E, Sayer PJ, Wang JC, and Fisher LM (1995) Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase IIβ. J Biol Chem 270:15739-15746.
3. Baguley BC, Leteurtre F, Riou J-F, Finlay GJ, and Pommier Y (1997) A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine. Eur J Cancer 33:272-279.
4. Beese LR and Steitz TA (1991) Structural basis for the 3′-5′ exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism. EMBO (Eur Mol Biol Organ) J 10:25-33.
5. Berger JM, Gamblin SJ, Harrison SC, and Wang JC (1996) Structure and mechanism of DNA topoisomerase II. Nature (Lond) 379:225-232.
6. Capranico G, Guano F, Moro S, Zagotto G, Sissi C, Gatto B, Zunino F, Menta E, and Palumbo M (1998) Mapping drug interactions at the covalent topoisomerase II-DNA complex by bisantrene/amsacrine congeners. J Biol Chem 273:12732-12739.
7. Errington F, Willmore E, Leontiou C, Tilby MJ, and Austin CA (2004) Differences in the longevity of topoIIα and topoIIβ drug-stabilised cleavable complexes and the relationship to drug sensitivity. Cancer Chemother Pharmacol 53:155-162.
8. Errington F, Willmore E, Tilby MJ, Li L, Li G, Li W, Baguley BC, and Austin CA (1999) Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol 56:1309-1316.
9. Finlay GJ, Riou JF, and Baguley BC (1996) From Amsacrine to DACA (N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide): selectivity fro topoisomerases I and II among acridine derivatives. Eur J Cancer 32A:708-714.
10. Fisher LM, Lawrence JM, Josty IC, Hopewell R, Margerrison EE, and Cullen ME (1989) Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance. Am J Med 87:2S-8S.
11. Gilroy KL, Leontiou C, Padget K, Lakey JH, and Austin CA (2006) mAMSA resistant human topoisomerase IIβ mutation G465D has reduced ATP hydrolysis activity. Nucleic Acids Res 34:1597-1607.
12. Hinds M, Deisseroth K, Mayes J, Altschuler E, Jansen R, Ledley FD, and Zwelling LA (1991) Identification of a point mutation in the topoisomerase II gene from a human leukaemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res 51:4729-4731.
13. Huff AC and Kreuzer KN (1990) Evidence for a common mechanism of action for antitumor and antibacterial agents that inhibit type II DNA topoisomerases. J Biol Chem 265:20496-20505.
14. Jehn U (1989) New drugs in the treatment of acute and chronic leukaemia: current role of mAMSA. Bone Marrow Transplant 4 (Suppl 3):53-58.
15. Jensen LH, Wessel I, Moller M, Nitiss JL, Sehested M, and Jensen PB (2000) N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperzine resistance. FEBS Lett 480:201-207.
16. Lee M-S, Wang JC, and Beran M (1992) Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation on the 170 kDa form of human topoisomerase II. J Mol Biol 223:837-843.
17. Leontiou C, Lakey JH, and Austin CA (2004) Mutation E522K in human DNA topoisomerase IIβ confers resistance to methyl N-(4′-(9- acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4′-(9- acridinylamino)-3-methoxyphenyl) methane sulphonamide but hypersensitivity to etoposide. Mol Pharmacol 66:430-439.
18. Leontiou C, Lakey JH, Lightowlers R, Turnbull RM, and Austin CA (2006) Mutation P732L in human DNA topoisomerase IIβ abolishes DNA cleavage in the presence of calcium and confers drug resistance. Mol Pharmacol 69:130-139.
19. Leontiou C, Lightowlers R, Lakey JH, and Austin CA (2003) Kinetic analysis of human topoisomerase IIalpha and beta DNA binding by surface plasmon resonance. FEBS Lett 554:206-210.
20. Marsh KL, Willmore E, Tinelli S, Cornarotti M, Meczes EL, Capranico G, Fisher LM, and Austin CA (1996) Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms α and β. Biochem Pharmacol 52:1675-1685.
21. Meczes EL, Marsh KL, Fisher LM, Roger MP, and Austin CA (1997) Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2 beta construct allows the study of topoisomerase II beta inhibitors in yeast. Cancer Chemother Pharmacol 39:367-375.
22. Moreland N, Finlay GJ, Dragunow M, Holdaway KM, and Baguley BC (1997) Cellular responses to methyl-N-[4-(9-acridinylamino)-2-methoxy[henyl] carbamate hydrochloride, an analogue of amsacrinective against non-proliferating cells. Eur J Cancer 33:1668-1676.
23. Nitiss JL (1994) Using yeast to study resistance to topoisomerase II-targeting drugs. Cancer Chemother Pharmacol 34 (Suppl):S6-S13.
24. Noble CG and Maxwell A (2002) The role of GyrB in the DNA cleavage-religation reaction of DNA gyrase: a proposed two metal-ion mechanism. J Mol Biol 318:361-371.
25. Padget K, Pearson AD, and Austin CA (2000) Quantitation of DNA topoisomerase II alpha and beta in human leukaemia cells by immunoblotting. Leukemia 14:1997-2005.
26. Pan X-S, Ambler J, Mehtar S, and Fisher LM (1996) Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 40:2321-2326.
27. Patel S, Keller BA, and Fisher LM (2000) Mutations at Arg486 and Glu571 in Human Topoisomerase IIα Confer Resistance to Amsacrine: Relevance for Antitumor Drug Resistance in Human Cells. Mol Pharmacol 57:784-791.
28. Pommier Y (1993) DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother Pharmacol 32:103-108.
29. Turnbull RM, Meczes EL, Perenna Rogers M, Lock RB, Sullivan DM, Finlay GJ, Baguley BC, and Austin CA (1999) Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIα and β. Cancer Chemother Pharmacol 44:275-282.
30. Wasserman R and Wang JC (1994) Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine. Cancer Res 54:1795-1800.
31. West KL, Meczes EL, Thorn R, Turnbull RM, Marshall R, and Austin CA (2000) Mutagenesis of E477 or K505 in the B′ domain of human topoisomerase II beta increases the requirement for magnesium ions during strand passage. Biochemistry 39:1223-1233.
32. Willmore E, Frank AJ, Padget K, Tilby MJ, and Austin CA (1998) Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform - specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Mol Pharmacol 54:78-85.
33. Wulfert M, Tapprich C, and Gattermann N (2006) Optimized PCR fragments for heteroduplex analysis of the whole human mitochondrial genome with denaturing HPLC. J Chromatogr B 831:236-247.